Phase II trial of encapsulated rapamycin to reduce polyp burden associated with familial adenomatous polyposis
{{output}}
Purpose: Familial adenomatous polyposis (FAP) confers a significant risk of colorectal/duodenal cancer. Encapsulated rapamycin (eRapa) has demonstrated promise as FAP chemoprevention in early clinical studies. ... ...
